企业档案
- 会员类型：免费会员
- 工商认证： 【已认证】
- 最后认证时间：
- 法人：
- 注册号：****
- 企业类型：生产商
- 注册资金：人民币万
实验动物
- LEWIS大鼠
- 129/Se小鼠
- F344大鼠
- C3H/He
- BN大鼠
- CBA/ca小鼠
- DBA/2小鼠
- BALB/c-nu裸鼠
- F1代小鼠
- BALB/c小鼠
- KM小鼠
- ICR小鼠
- Wistar大鼠
- SD大鼠
- C57小鼠
抗体
核酸类试剂盒
生化检测试剂盒
标签抗体
对照品
标准品
原代细胞总RNA
ELISA试剂盒
食品检测试剂盒
梯希爱（TCI）试剂
细胞检测试剂盒
细胞
培养基
血清
细胞因子
多肽
其他生化试剂类
缓存剂类
表面活性剂
分离材料及耗材
维生素类
色素类
碳水化合物类
植物激素及核酸类
抗生素类
蛋白质类
氨基酸类
酶类
水产病害类试剂盒
致病微生物系列试剂盒
转基因农产品试剂盒
公共卫生检疫试剂盒
传染病类诊断制剂
禽病类检测试剂盒
猪病类检测试剂盒
联系我们
联系人：邓冉
热门标签
公司动态
神经干细胞移植在极罕见脑病中显现治疗潜力
13年8月3日讯 /BIOON/ －－StemCells公司今天公布的数据显示，移植了该公司专有的HuCNS-SC（纯化的人类神经干细胞）后的佩-梅病（Pelizaeus-Merzbacher disease，PMD）患者，经磁共振成像（MRI）表明，移植2年后，髓鞘的形成比移植1年后更加明显，同时，患者移植1年后所获得的神经功能临床收益，在2年后仍能继续维持，并且未出现安全性问题。
佩-梅病（Pelizaeus-Merzbacherdisease，PMD）是一种罕见的弥漫性脑白质髓鞘形成障碍的X连锁隐性遗传疾病，由于基因缺陷，导致大脑中髓磷脂不足，*终导致神经功能的逐渐丧失和死亡。
StemCells公司从事基于干细胞疗法和工具的研究、开发和商品化，用于基于干细胞的研究和药物发现。该公司目前开发的先导治疗候选产品HuCNS-SC（纯化的人类神经干细胞），有望用于广泛的中枢神经系统紊乱疾病的治疗。（Bioon.com）
英文原文：Stem cell transplants show potential in patients with extremely rare brain disease
NEWARK, Calif., Aug. 2, 2013 （GLOBE NEWSWIRE） －－ StemCells, Inc. （Nasdaq:STEM） today presented data which show that two years after transplantation of the Company＇s proprietary HuCNS-SC? cells （purified human neural stem cells） into patients with Pelizaeus-Merzbacher disease （PMD）, the evidence of myelination, by magnetic resonance imaging （MRI）, is more pronounced compared to one year post-transplantation, the gains in neurological function reported after one year were maintained, ａnd there were no safety concerns. Patients with PMD have a defective gene which leads to insufficient myelin in the brain, resulting in progressive loss of neurological function ａnd death. The neurological ａnd MRI changes suggest a departure from the natural history of the disease ａnd may represent signals of a clinical effect. The data was presented today by Stephen Huhn, MD, FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc., at the 2013 Pelizaeus-Merzbacher Disease Symposium ａnd Health Fair being held at Nemours/Alfred I. duPont Children＇s Hospital in Wilmington, Del.
"We are encouraged that the MRI data continue to indicate new ａnd durable myelination related to the transplanted cells ａnd that the data is even stronger after two years compared to one year," said Dr. Huhn. "Even in the context of a small open-label study, these MRI results, measured at time points long after transplantation, make an even more convincing case that the HuCNS-SC cells are biologically active ａnd that their effect is measureable, sustainable ａnd progressive. Our challenge now is to reach agreement with the FDA on how best to correlate changes in MRI with meaningful clinical benefit, as this will be a critical step in determining a viable registration pathway for PMD."
In the Company＇s Phase I trial, which was conducted at the University of California, San Francisco, four patients with connatal PMD, the most severe form of the disease, were enrolLED ａnd transplanted with HuCNS-SC cells. The patients were followed for twelve months after transplantation, during which time they underwent intensive neurological assessments ａnd magnetic resonance imaging at regular intervals. The Phase I trial results indicate a favorable safety profile for the HuCNS-SC cells ａnd the transplantation procedure. Analysis of the MRI data showed changes consistent with increased myelination in the region of the transplantation, which progressed over time ａnd persisted after the withdrawal of immunosuppression at nine months. The results support the conclusion of durable cell engraftment ａnd donor cell-derived myelin in the transplanted patients＇ brains. In addition, clinical assessment revealed small but measureable gains in motor and/or cognitive function in three of the four patients; the fourth patient remained clinically stable. The Phase I trial results were published in October 2012 in Science Translational Medicine, the peer review journal of the American Association for the Advancement of Science. Upon completion of the Phase I trial, all four patients were enrolled into a long-term follow up study, which is designed to follow the patients for four more years.
The Pelizaeus-Merzbacher Disease Symposium ａnd Health Fair is intended to help educate families ａnd healthcare professionals about PMD ａnd related disorders. Sponsors include The PMD Foundation, a non-profit organization formed to raise awareness of the disease, create support for people with PMD, reduce misdiagnosis of PMD, ａnd fund scientific research, ａnd Nemours Biomedical Research, a branch of the Nemours Foundation, which is dedicated to improving the health ａnd health care of all children.
